What is the purpose of this trial?
Currently, autism is diagnosed and treated based on information gathered from clinical assessments and parent questionnaires. ABC-CT will add to this pool of knowledge by developing a more objective battery of tools to measure social function. Using EEG to measure brain function, eye tracking technology to measure visual attention, and automated recording techniques to assess behavior and speech, children aged 6 to 11 will be monitored over a six-month period. In addition to the behavioral measures and biomarker data, this community resource will also include DNA samples from children with ASD and their parents for use in future genetic studies. The consortium will establish a technical and data infrastructure for reliably measuring social function, allowing the collaborating sites to work together as a single unit. The goal is to create a set of measures that can be used in clinical trials to determine which treatments are best for which patients and who will benefit from a particular treatment. The ultimate goal is to validate a set of tools that will enable clinicians to objectively measure and predict how children with ASD respond to treatment.
The Autism Biomarkers Consortium for Clinical Trials (ABC-CT) is seeking families to participate in a study to improve diagnosis and treatment in Autism Spectrum Disorder (ASD). We are currently recruiting both typically developing children and children with a diagnosis of ASD between the ages of 6 and 11 years old.
Ages: 6 - 11 years
National Institute of Mental Health
Dates: 12/08/2015 - 11/01/2018
Last Updated: 12/10/2017
Study HIC#: 1509016477